

SUPPLEMENT



**SUPPLEMENTARY FIGURE. 1.** Trial protocol. Radiotherapy was given 5 days/week for 5 weeks (arrows) for a total of 45 Gy, with a minimum boost of 5.4 Gy. Fluorouracil was given as a 225-mg/m2/day continuous infusion for 7 days/week during radiation therapy for 5–6 weeks, depending on the number of radiation boosts given. mFOLFOX6 was given in 2-week cycles of leucovorin 200 mg/m2 or 400 mg/m2 and oxaliplatin 85 mg/m2 in a 2-h infusion, bolus fluorouracil 400 mg/m2 on day 1, and a 46-h infusion of fluorouracil 2400 mg/m2. \*Interim assessments were performed by proctoscopic examination; total mesorectal excision was performed if the patient had stable or progressive disease. (Reprinted with permission from Lancet Oncol. 16:957–966, 2015.)



**SUPPLEMENTARY FIGURE. 2.** Kaplan-Meier curves of disease-free survival (with numbers of subjects at risk at the bottom) for patients who did not receive any chemotherapy cycles after CRT (Ø cycles) and patients who received at least 1 chemotherapy cycle, either as consolidation chemotherapy after CRT, as adjuvant chemotherapy after TME, or both.

**SUPPLEMENTARY TABLE 1.** Baseline patient characteristics in relation to follow-up availability

|  |  |  |
| --- | --- | --- |
| *Characteristic* | *No. of patients (%)* | |
| *Follow-up available (n = 211)* | *Follow-up not available (n = 48)* |
| Study group | | |
| SG1 | 40 (19) | 20 (42) |
| SG2 | 56 (27) | 11 (23) |
| SG3 | 53 (25) | 14 (29) |
| SG4 | 62 (29) | 3 (6) |
|  |  |  |
| Age (years; mean ± SD) | 57 ± 11 | 59 ± 11 |
|  |  |  |
| Sex | | |
| Male | 124 (59) | 28 (58) |
| Female | 87 (41) | 20 (42) |
|  |  |  |
| ECOG*a* performance status | | |
| 0 | 179 (85) | 43 (90) |
| 1 | 32 (15) | 5 (10) |
|  |  |  |
| Clinical stage | | |
| II | 50 (24) | 14 (29) |
| III | 161 (76) | 34 (71) |
|  |  |  |
| Distance from anal verge (cm; mean ± SD) | 6.8 ± 3.2 | 6.9 ± 2.9 |
|  |  |  |
| ypTNM stage | | |
| 0 | 65 (31) | 16 (33) |
| I | 58 (28) | 11 (23) |
| II | 41 (19) | 13 (27) |
| III | 47 (22) | 8 (17) |
|  |  |  |
| Pathological complete response | | |
| Yes | 58 (27) | 15 (31) |
| No | 153 (73) | 33 (69) |

*a*ECOG, Eastern Collaborative Oncology Group.